Our group develops 3D tumor-on-chip systems to study metastatic dormancy and reactivation. These platforms allow us to model vascular and stromal niches, integrate redox biology, and map dormancy markers. We test how RNA-based therapeutics and PARP inhibitors influence reactivation, with the aim of preventing relapse.